Can’t Stop Buying This Dividend Juggernaut: ABBV Growth
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
Compare rebalancing frequency between index funds and target-date funds and what that means for risk, fees, and long-term performance. A quick look at when to expect adjustments.
28,361 articlesA long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
The crisis now in its third week intensified after a missile strike on the U.S. embassy in Baghdad and a fuel facilit...
GM authorized a $6 billion buyback and boosted its dividend, signaling a shift toward disciplined cash returns. Ford,...
A 71-year-old stroke survivor hit the in-network out-of-pocket maximum of a zero-premium Medicare Advantage plan, und...
A 73-year-old worker with an $800,000 401(K) cannot roll it into a new IRA after leaving a former employer, revealing...
A podcast recap attributes a Bezos stance to exempting the bottom half from federal income taxes, highlighting a broa...
NovaCore Technologies enters the second half of 2026 with a multi-year backlog, AI revenue momentum, and cloud growth...
Bitcoin faces renewed pressure as a large overnight repo operation from the Federal Reserve coincides with stress in ...
SanDisk announced a $1 billion strategic equity investment in Nanya Technology, prompting a roughly 6% share decline ...
Oil majors are again tightening the net on mid-cap energy producers. Three energy plays stand out as takeover candida...
US spot Bitcoin ETFs posted another day of outflows on June 30, extending a nine-day streak and signaling a broader c...
The State of the Union delivered broad economic themes, but housing policy specifics were scarce, prompting questions...